Coronavirus continues to wreak havoc in the country. There have been 3,62,727 new cases of corona in the country in the last 24 hours. At the same time, 4,120 people have lost their lives due to this epidemic. Meanwhile, India has got a good news soon in the war against Corona. In fact, the Drugs Controller General of India (DCGI) on Thursday approved the second and third phase clinical trials of COVAXIN in the age group of 2-18. Bharat Biotech will conduct trials on 525 healthy volunteers.
Earlier, an expert panel of Bharat Biotech’s Covaxin Bharat Biotech recommended approval for the second and third stage trials for ages 2 to 18 years. According to the official sources, this trial will be done at AIIMS in Delhi and Patna and several other places including the Meditrina Medical Science Institute in Nagpur.